Editor's Note Glucagon-like peptide-1 receptor agonists (GLP-1s) could reduce total knee arthroplasty (TKA) complications for non-diabetic patients with obesity, according to a November 13 Helio report on research presented at the American Association of Hip and Knee Surgeons Annual Meeting. In addition to reduced odds of 90-day medical complications, the…

Read More

Editor's Note The US Food and Drug Administration (FDA) has updated the labels of all treatments containing GLP-1 receptor agonists with a warning about warning about pulmonary aspiration during general anesthesia or deep sedation. Drugs and brand names listed in a November 8 report on the development from MedPage Today…

Read More

Editor's Note Joint guidance from key US medical associations advises that most patients on GLP-1 weight-loss medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), may safely continue these drugs before surgery, HealthDay News reported October 31. Concerns had emerged about potential risks associated with these medications due to their…

Read More

Editor's Note Combining newer weight loss drugs with bariatric surgery is the most cost-effective long-term strategy for treating obesity, according to research presented at the American College of Surgeons Clinical Congress 2024. Medical Xpress reported on the findings October 18. According to the article, researchers from Northwestern Medicine evaluated the…

Read More

Editor's Note Patients using GLP-1 receptor agonists (GLP-1 RAs) have a higher risk of food retention during esophagogastroduodenoscopy (EGD) when performed alone, but not when combined with a colonoscopy, according to a retrospective study from Cedars-Sinai Medical Center. MedPage Today reported the news October 1. The study included 70 patients…

Read More

Editor's Note Patients prescribed a glucagon-like peptide-1 agonist (GLP-1) showed higher postoperative infection rates after ankle-fusion procedures in a study presented at the annual meeting of the American Orthopaedic Foot & Ankle Society. Healio reported the news September 20.   Conducted by a team at the Milton S. Hershey Medical…

Read More

Editor's Note A shuttered bariatric surgery center in Oklahoma last month is just one example of how the rise of Glucagon-like peptide-1 (GLP-1) agonists are reshaping health systems’ investments, Axios reported August 13. Rather than “massive hospital towers with cardiology clinics, dialysis beds and joint replacement centers,” the focus is…

Read More

Editor's Note For diabetic patients with obesity and chronic kidney disease (CKD), metabolic bariatric surgery could protect the kidneys better than therapy with glucagon-like peptide-1 receptor agonists (GLP-1RA), according to research published in the September issue of the Annals of Surgery. Conducted at a large US health system, the study…

Read More

Editor's Note Bariatric surgery provides longer-lasting, more effective weight loss than GLP-1 receptor agonists and lifestyle interventions, according to systematic reviews of medical literature from 2020 to 2024. Medical Xpress reported the news June 11. Presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting,…

Read More

Editor's Note Preoperative use of GLP-1 receptor agonists (RA) medications such as Ozempic and Wegovy is safe, according to a study published in the June issue of the American Journal of Gastroenterology. Controversy has swirled around these drugs due to the risk of slowed stomach emptying increasing a patient’s odds…

Read More